Estimating risks from modern breast cancer radiotherapy: Implications for clinical decision-making, risk management and radiation protection
Breast cancer is the most common cancer among women in Canada. Adjuvant radiotherapy is received by most patients as part of their treatment, as it has been shown to reduce the risk of breast cancer recurrence and mortality. However, randomized trials have shown that breast cancer radiotherapy can also increase the risks of heart disease […]
Transport of Radioactive Materials in Canada in 2021 and 2022
Canada is one of the world’s leading producers, users and exporters of nuclear fuel cycle products and radioisotopes for industrial, medical and research purposes. Based upon a survey conducted by the IAEA in the early 1980s, Canada was the second largest shipper of radioactive material (RAM) packages of all reporting countries. According to a survey […]
Update on the proposed regulatory review of the Class II Nuclear Facility and Prescribed Equipment Regulations (C2NFPER)
In the autumn of 2022, CNSC briefed stakeholders on the proposed changes to the C2NFPER via public workshops and a discussion paper. This presentation will provide an update on the project, with a focus on what we heard from commenters following the 2022 workshops and discussion paper.